Fig. 5.

Development of a siRNA-Based PKD1 Suppression Model

A, The efficacy for each of the expression cassettes (oligo1, oligo2, and oligo3) to suppress PKD1 expression in the M1-CCD cell line was investigated by Western blotting. M1-CCD cells were transfected with equivalent amounts (50 ng) of each of the PKD1 siRNA expression cassettes or a GAPDH kit control. Lysates were prepared and Western blotted using a PKD1-specific antibody. A β-actin-specific antibody was used as a loading control. B, The efficacy of PKD1 suppression in a stable cell line knockdown (KD) harboring oligo3 siRNA expression cassette ligated into pSEC-Neo was compared with untransfected wild-type (WT) or empty vector control (C) transfected cells. Lysates were prepared and Western blotted using a PKD1-specific antibody. A β-actin-specific antibody was used as a loading control.